Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mizuho Medy Co Ltd operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for Mizuho Medy Co's Operating Margin % or its related term are showing as below:
TSE:4595'
s Operating Margin % Range Over the Past 10 Years
Min: 9.9 Med: 30.16 Max: 63.16
Current: 31.49
TSE:4595's Operating Margin % is ranked better than 94.68% of 959
companies
in the Drug Manufacturers industry
Industry Median: 7.59
vs TSE:4595: 31.49
Mizuho Medy Co's 5-Year Average Operating Margin % Growth Rate was 19.70% per year.
Mizuho Medy Co (TSE:4595) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Mizuho Medy Co Operating Margin % Related Terms
Mizuho Medy Co Operating Margin % Historical Data
* Premium members only.
The historical data trend for Mizuho Medy Co's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4595 vs ZTS, UTHR: Operating Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Mizuho Medy Co's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mizuho Medy Co Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mizuho Medy Co's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Mizuho Medy Co's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Mizuho Medy Co's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mizuho Medy Co (TSE:4595) has a Operating Margin % of 0.00% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Mizuho Medy Co and its competitors. Over the past decade, Mizuho Medy Co's Operating Margin % has ranged from 9.90 to 63.16. According to the industry distribution chart, Mizuho Medy Co ranks #51 out of 959 companies in the Drug Manufacturers industry, placing it in the top 5.3%.
Is Mizuho Medy Co's Operating Margin % too high?
Mizuho Medy Co's current Operating Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 9.90 to a high of 63.16. Based on the distribution chart, Mizuho Medy Co ranks #51 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Mizuho Medy Co has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mizuho Medy Co's Operating Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Mizuho Medy Co ranks #51 out of 959 companies for Operating Margin %. This places Mizuho Medy Co in the top 5% of its industry — outperforming the majority of peers. The industry median Operating Margin % is 7.59. Historically, Mizuho Medy Co's own Operating Margin % has ranged from 9.90 to 63.16 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.59, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Mizuho Medy Co and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mizuho Medy Co's current Operating Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mizuho Medy Co stock overvalued right now?
Based on GuruFocus' analysis, Mizuho Medy Co (TSE:4595) is currently considered Modestly Overvalued. The stock's GF Value™ is 円1,440.52, compared to a current price of 円1,662.00 — trading 15.4% above its estimated fair value. The current Operating Margin % is 0.00%. Mizuho Medy Co's overall GF Score™ is 84/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Mizuho Medy Co (TSE:4595), the current Operating Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mizuho Medy Co (TSE:4595) Overvalued in 2026?
Based on GuruFocus' analysis, Mizuho Medy Co stock appears to be overvalued.
The current stock price of 円1,662.00 is trading 15.4% above its estimated GF Value™ of 円1,440.52.
GuruFocus considers Mizuho Medy Co to be Modestly Overvalued.
Key valuation signals for TSE:4595:
Operating Margin %: 0.00%
GF Value™: 円1,440.52 vs. price of 円1,662.00 (15.4% above fair value)
No single metric tells the full story. See the TSE:4595 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mizuho Medy Co Ltd engages in research and development, manufacture, and distribution of in-vitro diagnostic products. The company provides immuno assay test products, such as influenza virus kits; Infectious diseases test kits; fecal occult blood test kits for detection of human hemoglobin and human transferrin in feces; and biochemical liquid stable reagents for professionals. It also offers HCG (midstream test), including a digital p-check test for OTC. It also offers fruit tree virus test drugs to agricultural testing places.
84GF Score
Get the complete analysis for TSE:4595
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4595 has been successfully added to your 
